Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder

Por Michaelson, M D, Shipley, W U, Heney, N M, Zietman, A L, Kaufman, D S
Publicado em 2004

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma

Por Cella, D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Michaelson, M D, Motzer, R J
Publicado em 2012

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α

Por Patil, S, Figlin, R A, Hutson, T E, Michaelson, M D, Negrier, S, Kim, S T, Huang, X, Motzer, R J
Publicado em 2012

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis...

Por Cella, D, Michaelson, M D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Kim, S T, Li, J Z, Motzer, R J
Publicado em 2010

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study

Por Michaelson, M D, Zhu, A X, Ryan, D P, McDermott, D F, Shapiro, G I, Tye, L, Chen, I, Stephenson, P, Patyna, S, Ruiz-Garcia, A, Schwarzberg, A B
Publicado em 2013

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

Por Michaelson, M. D., Bellmunt, J., Hudes, G. R., Goel, S., Lee, R. J., Kantoff, P. W., Stein, C. A., Lardelli, P., Pardos, I., Kahatt, C., Nieto, A., Cullell-Young, M., Lewis, N. L., Smith, M. R.
Publicado em 2012

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Por Escudier, B, Michaelson, M D, Motzer, R J, Hutson, T E, Clark, J I, Lim, H Y, Porfiri, E, Zalewski, P, Kannourakis, G, Staehler, M, Tarazi, J, Rosbrook, B, Cisar, L, Hariharan, S, Kim, S, Rini, B I
Publicado em 2014